## CONTENTS

<table>
<thead>
<tr>
<th>Chapter Title</th>
<th>Page no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 1</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>1-14</td>
</tr>
<tr>
<td>Chapter 2</td>
<td></td>
</tr>
<tr>
<td>Review of Literature</td>
<td>15- 63</td>
</tr>
<tr>
<td>Chapter 3</td>
<td></td>
</tr>
<tr>
<td>Foreign Direct Investment in India: Concept, Regulatory Framework and Growth</td>
<td>64- 91</td>
</tr>
<tr>
<td>Chapter 4</td>
<td></td>
</tr>
<tr>
<td>Indian Pharmaceutical Industry: An Overview</td>
<td>92- 127</td>
</tr>
<tr>
<td>Chapter 5</td>
<td></td>
</tr>
<tr>
<td>Financial Performance of Select FDI-based Companies: An Analysis</td>
<td>128- 250</td>
</tr>
<tr>
<td>Chapter 6</td>
<td></td>
</tr>
<tr>
<td>A Comparative Analysis of the Financial Performance of FDI and Non-FDI Companies</td>
<td>251- 269</td>
</tr>
<tr>
<td>Chapter 7</td>
<td></td>
</tr>
<tr>
<td>Impact of FDI on the Growth of Pharmaceutical Sector in India</td>
<td>270- 329</td>
</tr>
<tr>
<td>Chapter 8</td>
<td></td>
</tr>
<tr>
<td>Summary, Findings, Suggestions and Conclusion</td>
<td>330- 348</td>
</tr>
<tr>
<td>Bibliography</td>
<td>349- 374</td>
</tr>
<tr>
<td>Annexures</td>
<td></td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page no.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chapter 1</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td></td>
</tr>
<tr>
<td>1.1 Introduction</td>
<td>1</td>
</tr>
<tr>
<td>1.2 Growing Importance of FDI</td>
<td>3</td>
</tr>
<tr>
<td>1.3 Indian Pharmaceutical Sector</td>
<td>4</td>
</tr>
<tr>
<td>1.4 Summary of Review of Literature</td>
<td>7</td>
</tr>
<tr>
<td>1.4.1 Research Gap</td>
<td>8</td>
</tr>
<tr>
<td>1.5 Need for the Study</td>
<td>9</td>
</tr>
<tr>
<td>1.6 Objectives of study</td>
<td>10</td>
</tr>
<tr>
<td>1.7 Hypotheses of the study</td>
<td>11</td>
</tr>
<tr>
<td>1.8 Methodology of the study</td>
<td>11</td>
</tr>
<tr>
<td>1.8.1 Sample Selection</td>
<td>12</td>
</tr>
<tr>
<td>1.9 Scope of the study</td>
<td>13</td>
</tr>
<tr>
<td>1.10 Limitations of the study</td>
<td>13</td>
</tr>
<tr>
<td>1.11 Chapterisation Scheme</td>
<td>13</td>
</tr>
<tr>
<td><strong>Chapter 2</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Review of Literature</strong></td>
<td>15-63</td>
</tr>
<tr>
<td>2.1 Studies on FDI in General</td>
<td>16</td>
</tr>
<tr>
<td>2.2 Studies on the impact of FDI</td>
<td>27</td>
</tr>
<tr>
<td>2.3 Summary of Literature Review</td>
<td>47</td>
</tr>
<tr>
<td>2.4 Research gap</td>
<td>49</td>
</tr>
</tbody>
</table>
Chapter 3

Foreign Direct Investment in India: Concept, Regulatory Framework and Growth 64-91

3.1 Introduction 64

3.2 Concept of FDI 64

3.2.1 Inclusion of ADR/GDR under FDI 64

3.2.2 Balance of Payment Effect 65

3.2.3 Grants 65

3.2.4 Investments In Unincorporated Entity 66

3.2.5 Foreign Currency Convertible Bonds 66

3.2.6 Control Premium, Non-Competition Fee 66

3.3 FDI Definitions 66

3.3.1 IMF BPM6 Definition 66

3.3.2 IMF BPM5 Definition 67

3.3.3 UNCTAD Definition 67

3.3.4 OECD Benchmark Definition, 4th Edition 68

3.3.5 OECD Benchmark Definition, 3rd Edition 71

3.3.6 Standard Statistical Requirements 71

3.4 FDI Entry Routes and Caps 72

3.4.1 Entry Routes for FDI inflows 72

3.4.2 Foreign Investment Promotion Board 74

3.4.3 Foreign Investment Promotion Council 75

3.4.4 FDI CAPS 76

3.5 FDI Policy in India 76

3.5.1 FDI Policy since 1991 77

3.5.2 FDI Policy 2006 78
3.5.3 FDI Policy 2010  
3.6 Foreign Investment Inflows in India  
3.6.1 FDI Equity inflows in India since 1991  
3.6.2 Country-wise FDI inflows in India since 1991  
3.6.3 Sector-wise FDI inflows in India since 1991  
3.6.4 FDI inflows in India in the Post-liberalization Period  
3.6.5 Growth rate of FDI inflows in India  

**Chapter 4**

**Indian Pharmaceutical Industry: An Overview**

4.1 Introduction  
4.2 Global Pharmaceutical Market  
4.3 History Indian Pharmaceutical Industry  
4.4 Growth of Indian Pharmaceutical Industry  
4.5 Indian Pharmaceutical Industry and TRIPS  
4.6 Indian Pharmaceutical Industry and R & D  
4.7 Six Sigma in Indian Pharmaceutical Industry  
4.8 Mergers and Acquisitions in Indian Pharmaceutical Industry  
4.9 Global Recession and Indian Pharmaceutical Industry  
4.10 Foreign Direct investment in Indian Pharmaceutical Sector  
4.10.1 Trends of FDI inflows in India and Pharmaceutical Sector  
4.10.2 Growth of FDI inflows in India and Pharmaceutical Sector  
4.10.3 Impact of FDI inflows in India on FDI inflows in the Pharmaceutical Sector  
4.10.4 Indian Pharmaceutical Industry and FDI- Government Initiatives  
4.11 Indian Pharmaceutical Industry - A SWOT Analysis  
4.12 Brief Profile of the Select-FDI based Companies in the Indian Pharmaceutical Sector
Chapter 5

Financial Performance of Select FDI-based Companies: An Analysis 128-250

5.1 Financial Ratios considered for Analysis 128

5.2 Financial Performance of Abbott India Ltd 134

5.3 Financial Performance of Astrazeneca Pharma India Ltd 140

5.4 Financial Performance of Aventis Pharma Ltd. 146

5.5 Financial Performance of Biocon Ltd. 153

5.6 Financial Performance of Fresenius Kabi Oncology Ltd 160

5.7 Financial Performance of Fulford (India) Ltd 166

5.8 Financial Performance of Glaxosmithkline Pharmaceuticals Ltd. 173

5.9 Financial Performance of K D L Biotech Ltd. 179

5.10 Financial Performance of Kerala Ayurveda Ltd. 185

5.11 Financial Performance of Matrix Laboratories Ltd. 192

5.12 Financial Performance of Merck Ltd. 199

5.13 Financial Performance of Novartis India Ltd. 205

5.14 Financial Performance of Pfizer Ltd 212

5.15 Financial Performance of Ranbaxy Laboratories Ltd. 218

5.16 Financial Performance of Sandu Pharmaceuticals Ltd. 225

5.17 Financial Performance of Solvay Pharma India Ltd. 231

5.18 Financial Performance of Wanbury Ltd. 237

5.19 Financial Performance of Wyeth Ltd 244

Chapter 6

A Comparative Analysis of the Financial Performance of FDI and Non-FDI Companies 251-269

6.1 Analysis of Profitability 251

6.1.1 Net Profit Margin 251
6.1.2 Return on Total Assets 253
6.1.3 Return on Net Worth 254
6.1.4 Return on Capital Employed 255
6.2 Analysis of Liquidity 256
6.2.1 Current Ratio 256
6.2.2 Quick Ratio 257
6.3 Analysis of Long-Term Solvency 258
6.3.1 Debt-Equity Ratio 258
6.3.2 Proprietary Ratio 259
6.4 Analysis of Efficiency 260
6.4.1 Stock Turnover Ratio 260
6.4.2 Inventory Ratio 261
6.4.3 Assets Turnover Ratio 262
6.5 Analysis of Expenses 263
6.5.1 R&D Expenses Ratio 263
6.6 Analysis of Growth 265
6.6.1 Growth in Sales 265
6.6.2 Growth in PBIT 266
6.6.3 Growth in PAT 267
6.6.4 Growth in Assets 268

Chapter 7

Impact of FDI on the Growth of Pharmaceutical Sector in India 270-329
7.1 Impact of FDI on Select Financial Variables: An Analysis based on Individual Parameters 271
7.1.1 Impact of FDI on Sales 271
7.1.2 Impact of FDI on PBIT 274
7.1.3 Impact of FDI on Capital Employed 277
7.2 Impact of FDI on Select Financial Variables: An Analysis based on Aggregate Parameters 280
7.3 Impact of FDI on the Financial Performance of Selected FDI-based Pharmaceutical Companies – An Analysis based on Individual Parameters 281
7.3.1 Impact of FDI on Profitability 281
7.3.2 Impact of FDI on Liquidity 290
7.3.3 Impact of FDI on Long-term Solvency 294
7.3.4 Impact of FDI on Efficiency 300
7.3.5 Impact of FDI on Expenses 309
7.3.6 Impact of FDI on growth 312
7.4 Impact of FDI on the Financial Performance of Selected FDI-based Pharmaceutical Companies – An Analysis based on Aggregate Parameters. 325
    Test of hypotheses 328
    Summary Result of test of hypotheses 328

Chapter 8

Summary, Findings, Suggestions and Conclusion 330-348

8.1 Summary of the Study 330
8.2 Findings of the Study 333
8.3 Suggestions 346
8.4 Conclusion 348

Bibliography 349-374

Annexure-I
Annexure-II
Annexure-III
Annexure-IV